Get the Stockscreener App
176.91
11.26%
17.90
After Hours:
174.89
-2.02
-1.14%
Spruce Biosciences Inc stock is traded at $176.91, with a volume of 192.12K.
It is up +11.26% in the last 24 hours and down -67.44% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$159.01
Open:
$156.69
24h Volume:
192.12K
Relative Volume:
0.45
Market Cap:
$99.61M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-188.20
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-3.12%
1M Performance:
-67.44%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$156.69
$188.25
1-Week Range:
$138.01
$199.20
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
176.91 | 89.60M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Spruce Biosciences to sell 502,181 shares at $68.00 in private placement - MSN
Spruce Biosciences (NASDAQ:SPRB) Shares Down 1%What's Next? - MarketBeat
Medical Stocks To ConsiderOctober 6th - MarketBeat
Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat
Spruce Biosciences, Inc. announced that it has received $49.999769 million in funding - MarketScreener
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 By Investing.com - Investing.com Canada
Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 - Investing.com India
Spruce Biosciences announces $50M private placement financing - TipRanks
Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN
Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Th - GuruFocus
Spruce Biosciences to Raise $50 Million Through Private Placement; Shares Down Pre-Bell - MarketScreener
Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus
Spruce Biosciences secures $50 million in private placement - Investing.com
Spruce Biosciences secures $50 million in private placement By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - MSN
Spruce Biosciences announces $50.0 million private placement financing - MarketScreener
Spruce Biosciences Announces $50.0 Million Private Placement Financing - Business Wire
Small Cap Stocks To Follow Today – October 6th - Defense World
Medical Stocks To Consider – October 6th - Defense World
Three Biotech Stocks Jump After Big Regulatory Wins - Finimize
Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com
SPRB Stock Hits 19-Month High Amid Trading Halts - NewsBreak: Local News & Alerts
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
Spruce Biosciences Soars: What’s Driving the Surge? - timothysykes.com
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why - NewsBreak: Local News & Alerts
This Emerging Biotech Stock Jumped 1,300% on Monday After Major FDA Breakthrough Milestone - inkl
Why Did Spruce Biosciences Stock Quadruple Today? - Stocktwits
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
Spruce Biosciences Stock Surges: Analyzing Breakthrough - StocksToTrade
Spruce Biosciences (SPRB) Stock: Rare Disease Breakthrough Sends Shares Soaring Over 1,300% - parameter.io
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barron's
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Spruce Biosciences (SPRB) Stock Soars 1,378% on FDA Breakthrough Status - MoneyCheck
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside - MSN
Spruce Biosciences Almost Doubles Premarket as FDA Grants Breakthrough Therapy Designation for Tralesinidase Alfa in Sanfilippo Syndrome - MarketScreener
Why Is Spruce Biosciences Stock (SPRB) Surging Today? - TipRanks
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Spruce Biosciences Stock Resumes Trading: What to Expect? - timothysykes.com
Why This Biotech Stock Just Rocketed Almost 1,400% - Investor's Business Daily
Spruce Biosciences Surges on FDA Breakthrough: Is SPRB’s Rally Sustainable? - Azat TV
Why Spruce Biosciences Just Skyrocketed More Than 1,600% - inkl
SPRB’s Stock Market Moves: Key Insights - StocksToTrade
Spruce Biosciences (SPRB) Surges 1,244% on FDA Breakthrough Ther - GuruFocus
FDA Grants Breakthrough Therapy Status to Spruce Biosciences’ TA-ERT for MPS IIIB - el-balad.com
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade? - ts2.tech
SPRB’s Wild Ride: Understanding Today’s Market Move - timothysykes.com
Spruce Biosciences’ Blockchain Breakthrough - StocksToTrade
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spruce Biosciences Inc Stock (SPRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):